Shares of Zydus Lifesciences saw a decline of more than two percent following the announcement of a notable profit drop. The net profit plunged thirty-six percent year-on-year for the first quarter, despite a nearly twenty-two percent increase in operational revenue. Expenses surged by over forty-one percent. However, the managing director remains optimistic about future prospects. Analysts at Nuvama have upgraded the stock to ‘Buy’, setting a higher price target.
Dr Agarwals Health shares fall 7% after Rs 2,065-crore block deal; Hyperion Investments, Claymore likely sellers
Dr Agarwals Health Care shares dropped on Wednesday after a Rs 2,065-crore block deal involving 4.07 crore shares. Hyperion Investments and Claymore Investments were likely
August 12, 2026